Greater Copenhagen to be Europe's fertility R&D power centre

The EU invests DKK 57.5 million in the Danish-Swedish research project ReproUnion, which will create an internationally leading hub for the treatment of infertility.

Europe's fertility rates are gloomy. As a result, the EU now invests DKK 57.5 million in the Danish-Swedish research project ReproUnion.

The aim is to develop an internationally leading hub for the treatment of infertility and to produce research and results that will prevent and treat infertility across the EU. The ReproUnion project will create 25 PhD research positions, and 13 specialised departments in hospitals in Copenhagen, Malmö and Holbæk will get significant resource injections.

Infertility treatment beacon

The Oresund Region in Greater Copenhagen is already a leader in the treatment of infertility, among other things, because the treatment is free and because infertility is considered to be a medical disorder.

The free and equal access to healthcare and treatment as well as the region’s large patient base offer highly favourable conditions for public-private research. Moreover, the R&D funding from the EU creates a strong platform to attract the best researchers and companies from around the world to work and do research in the Greater Copenhagen region. The synergy between business and the public sector will have an impact beyond ReproUnion.

Among the investors is the company Ferring Pharmaceuticals:

"ReproUnion will attract talented scientists with international experience and, under the project, many patients will be monitored and treated. The development of new medicines to improve treatment requires large groups of patients in clinical research," said Per Cantor, Senior Vice President R&D, Ferring Pharmaceuticals.

The project will run three years starting from 1 September 2015.

Source: Newsbreak.dk (In Danish)